UNSPSC 51282008: Bacitracin zinc

This classification denotes an antibiotic with the molecular formula C66H103N17O16SZn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89Y4M234ES, chemically known as bacitracins, zinc complex, but more generally known as bacitracin zinc, which bears US NIH Compound Identifier 3083711. European Medicines Agency schedules bacitracin zinc or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Most nations, for tariff purposes, schedule bacitracin zinc under HS 29419000. SMILES:.

Bacitracin zinc bears US NLM identifiers UMLS ID C0043483 and NCI Concept Code C28857.

UNSPSC 51282008 Bacitracin zinc is a Commodity code covering antibiotic topical ointment products distributed through state and local government healthcare and institutional facilities. State and local governments procure bacitracin zinc primarily through cooperative purchasing agreements established to supply multiple agencies and jurisdictions with generic pharmaceutical inventory at negotiated rates. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body actively soliciting under this code, leveraging cooperative structures to consolidate demand across member states and local entities and achieve economies of scale. Vendors responding to MMCAP contracts must comply with cGMP certification, Drug Supply Chain Security Act (DSCSA) requirements, FDA compliance, and maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with chargebacks and EDI capability mandatory. Contracts require comprehensive insurance coverage including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability per occurrence.

MMCAP's footprint spans Minnesota, Oregon, and other participating member states within the multistate cooperative. The Minnesota Department of Administration issued a Request for Proposal (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, seeking manufacturers to supply generic multi-source pharmaceuticals and OTC products through authorized wholesalers effective July 1, 2026. Award decisions will be based on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), administrative fee agreement (5 percent), and price competitiveness (75 percent), with a two-year initial contract term and optional extensions at MMCAP's discretion. Vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties ranging from $200 to $1,500 per violation for reporting delays, missed onboarding timelines, or improper trade-class denials. Specific award values are not disclosed in the RFP materials.